CONTEXT: The age-related decline in dehydroepiandrosterone (DHEA) levels is thought to be of importance for general and vascular aging. However, data on the association between DHEA and mortality are conflicting. OBJECTIVES: We tested the hypothesis that low serum DHEA and DHEA sulfate (DHEA-S) levels predict all-cause and cardiovascular disease (CVD) death in elderly men. DESIGN, SETTING, AND PARTICIPANTS: We used gas/liquid chromatography-mass spectrometry to analyze baseline levels of DHEA and DHEA-S in the prospective population-based MrOS Sweden study (2644 men, aged 69-81 yr). Mortality data were obtained from central registers and analyzed using Cox proportional hazards regressions. MAIN OUTCOME MEASURES: All-cause and CVD mortality by serum DHEA(-S) levels. RESULTS: During a mean 4.5-yr follow-up, 328 deaths occurred. Low levels of DHEA-S (quartile 1 vs. quartiles 2-4), predicted death from all causes [hazard ratio (HR) 1.54, 95% confidence interval (CI) 1.21-1.96; adjusted for traditional cardiovascular risk factors], from CVD (n = 123 deaths; HR 1.61, 95% CI 1.10-2.37) and ischemic heart disease (n = 73; HR 1.67, 95% CI 1.02-2.74) but not cancer. Analyses with DHEA gave similar results. The association between low DHEA-S and CVD death remained after adjustment for C-reactive protein and circulating estradiol and testosterone levels. When stratified by the median age of 75.4 yr, the mortality prediction by low DHEA-S was more pronounced among younger (age adjusted HR for CVD death 2.64, 95% CI 1.37-5.09) than older men (HR 1.30, 95% CI 0.83-2.04). CONCLUSIONS: Low serum levels of DHEA(-S) predict death from all causes, CVD, and ischemic heart disease in older men.
CONTEXT: The age-related decline in dehydroepiandrosterone (DHEA) levels is thought to be of importance for general and vascular aging. However, data on the association between DHEA and mortality are conflicting. OBJECTIVES: We tested the hypothesis that low serum DHEA and DHEA sulfate (DHEA-S) levels predict all-cause and cardiovascular disease (CVD) death in elderly men. DESIGN, SETTING, AND PARTICIPANTS: We used gas/liquid chromatography-mass spectrometry to analyze baseline levels of DHEA and DHEA-S in the prospective population-based MrOS Sweden study (2644 men, aged 69-81 yr). Mortality data were obtained from central registers and analyzed using Cox proportional hazards regressions. MAIN OUTCOME MEASURES: All-cause and CVD mortality by serum DHEA(-S) levels. RESULTS: During a mean 4.5-yr follow-up, 328 deaths occurred. Low levels of DHEA-S (quartile 1 vs. quartiles 2-4), predicted death from all causes [hazard ratio (HR) 1.54, 95% confidence interval (CI) 1.21-1.96; adjusted for traditional cardiovascular risk factors], from CVD (n = 123 deaths; HR 1.61, 95% CI 1.10-2.37) and ischemic heart disease (n = 73; HR 1.67, 95% CI 1.02-2.74) but not cancer. Analyses with DHEA gave similar results. The association between low DHEA-S and CVD death remained after adjustment for C-reactive protein and circulating estradiol and testosterone levels. When stratified by the median age of 75.4 yr, the mortality prediction by low DHEA-S was more pronounced among younger (age adjusted HR for CVD death 2.64, 95% CI 1.37-5.09) than older men (HR 1.30, 95% CI 0.83-2.04). CONCLUSIONS: Low serum levels of DHEA(-S) predict death from all causes, CVD, and ischemic heart disease in older men.
Authors: Andrey I Egorov; Shannon M Griffin; Reagan R Converse; Jennifer N Styles; Elizabeth A Sams; Anthony Wilson; Laura E Jackson; Timothy J Wade Journal: Environ Res Date: 2017-07-11 Impact factor: 6.498
Authors: V Matulevicius; V Urbanavicius; S Lukosevicius; I Banisauskaite; G Donielaite; A Galkine Journal: Acta Endocrinol (Buchar) Date: 2021 Apr-Jun Impact factor: 0.877
Authors: Charles J Ryan; Arturo Molina; Jinhui Li; Thian Kheoh; Eric J Small; Christopher M Haqq; Russell P Grant; Johann S de Bono; Howard I Scher Journal: J Clin Oncol Date: 2013-07-01 Impact factor: 44.544
Authors: Claudine A Blum; Cornelia Mueller; Philipp Schuetz; Felix Fluri; Michael Trummler; Beat Mueller; Mira Katan; Mirjam Christ-Crain Journal: PLoS One Date: 2013-05-01 Impact factor: 3.240
Authors: Anna-Karin Lennartsson; Töres Theorell; Alan L Rockwood; Mark M Kushnir; Ingibjörg H Jonsdottir Journal: PLoS One Date: 2013-08-28 Impact factor: 3.240
Authors: Guangju Zhai; Alexander Teumer; Lisette Stolk; John R B Perry; Liesbeth Vandenput; Andrea D Coviello; Annemarie Koster; Jordana T Bell; Shalender Bhasin; Joel Eriksson; Anna Eriksson; Florian Ernst; Luigi Ferrucci; Timothy M Frayling; Daniel Glass; Elin Grundberg; Robin Haring; Asa K Hedman; Albert Hofman; Douglas P Kiel; Heyo K Kroemer; Yongmei Liu; Kathryn L Lunetta; Marcello Maggio; Mattias Lorentzon; Massimo Mangino; David Melzer; Iva Miljkovic; Alexandra Nica; Brenda W J H Penninx; Ramachandran S Vasan; Fernando Rivadeneira; Kerrin S Small; Nicole Soranzo; André G Uitterlinden; Henry Völzke; Scott G Wilson; Li Xi; Wei Vivian Zhuang; Tamara B Harris; Joanne M Murabito; Claes Ohlsson; Anna Murray; Frank H de Jong; Tim D Spector; Henri Wallaschofski Journal: PLoS Genet Date: 2011-04-14 Impact factor: 5.917